VKTX Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing innovative therapies aimed at treating metabolic and endocrine disorders. The companys flagship drug candidate, VK2809, is an orally administered, tissue-selective thyroid hormone receptor beta (TRß) agonist. VK2809 is currently undergoing Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), conditions linked to significant metabolic disturbances and liver damage. This investigational therapy aims to address the unmet medical need in these prevalent liver disorders by targeting specific thyroid hormone pathways to potentially improve liver health.
Viking Therapeutics is also advancing VK5211, an oral, non-steroidal selective androgen receptor modulator (SARM). VK5211 is in Phase II clinical trials and is being evaluated for its efficacy in aiding recovery following non-elective hip fracture surgery. This therapy could offer benefits in terms of enhancing muscle strength and functional recovery, which are crucial for patients undergoing rehabilitation after significant orthopedic injuries.
Additionally, the company is developing VK0612, an orally available drug candidate for type 2 diabetes, which is poised to enter Phase IIb trials. VK0612 represents an important advancement in diabetes treatment by potentially improving glycemic control and metabolic outcomes for patients with this chronic condition. Another notable drug in Vikings pipeline is VK0214, a selective TRß agonist specifically designed for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare genetic disorder affecting the adrenal glands and nervous system. VK0214 is aimed at addressing this rare, debilitating condition by targeting specific receptor pathways.
Founded in 2012 and headquartered in San Diego, California, Viking Therapeutics has positioned itself at the forefront of biopharmaceutical innovation with a strong focus on developing therapies that target critical pathways in metabolic and endocrine disorders. The companys diverse pipeline of novel drug candidates underscores its commitment to advancing treatment options for patients with challenging health conditions.
|
